NCT05794711 is a clinical trial of Surgical resection in Lung Adenocarcinoma, sponsored by Fudan University.

Who is sponsoring NCT05794711?

NCT05794711 is sponsored by Fudan University.

What drugs are being tested in NCT05794711?

Interventions in NCT05794711: Surgical resection.

What condition does NCT05794711 study?

NCT05794711 studies Lung Adenocarcinoma, Surgical Procedure, Unspecified, Pathology.

Is NCT05794711 still recruiting?

NCT05794711 is currently status unknown. Last updated 24 July 2023.

Last reviewed 2023-07-24 · How we verify

NCT05794711

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1015)

Status unknown Last updated 24 July 2023

What this trial tests

trial testing Surgical resection in Lung Adenocarcinoma in 1,063 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
31 December 2023

31 December 2024

Quick facts

Lead sponsor	Fudan University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,063
Start date	1 January 2022
Primary completion	31 December 2023
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

Surgical resection

Conditions studied

Lung Adenocarcinoma — all drugs for Lung Adenocarcinoma →
Surgical Procedure, Unspecified — all drugs for Surgical Procedure, Unspecified →
Pathology — all drugs for Pathology →

Sponsor

Fudan University

Who can join

Eligibility, any sex, with Lung Adenocarcinoma or Surgical Procedure, Unspecified. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is one of Eastern Cooperative Thoracic Oncology Projects (ECTOP-1015). The goal of this clinical trial is to confirm the concordance rate between intra-operative frozen section pathological diagnosis and post-operative paraffin embedded pathological diagnosis, and use this result to guide surgical treatment for early stage (cT1N0M0) lung adenocarcinomas.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Prediction of the pathological subtypes by intraoperative frozen section for patients with cT1N0M0 invasive lung adenocarcinoma (ECTOP-1015): a prospective multicenter study.
Fu Z, Shen X, Deng C, Cao H, et al · · 2024 · cited 7× · PMID 38781043 · DOI 10.1097/js9.0000000000001667

Verify or expand the search:

Other trials of Surgical resection

Trials testing the same drug.

NCT06487481 — Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma · Phase 1 · recruiting
NCT06908031 — SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer · Phase 2 · recruiting
NCT06504381 — DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma · Phase 1, PHASE2 · recruiting
NCT06575322 — Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depressio · recruiting
NCT06576180 — Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patie · recruiting

Other recruiting trials for Lung Adenocarcinoma

Currently open trials in the same condition.

NCT07481786 — Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases · Phase 3 · recruiting
NCT07219251 — Engagement of Veterans With Lung Cancer · NA · recruiting
NCT07235280 — Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma · EARLY_PHASE1 · recruiting
NCT07161713 — SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors · NA · recruiting
NCT07479095 — Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic · NA · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05794711 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 24 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05794711.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing